Talis Biomedical Corp Financials
This page shows Talis Biomedical Corp (TLIS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2023 annual data. Scores normalized against common benchmarks. How we calculate these scores
Talis Biomedical Corp has an operating margin of -3131.0%, meaning the company retains $-3131 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2392.8% the prior year.
Talis Biomedical Corp's revenue declined 55.7% year-over-year, from $4.8M to $2.1M. This contraction results in a growth score of 0/100.
Talis Biomedical Corp carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.86, Talis Biomedical Corp holds $8.86 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Talis Biomedical Corp generated -$53.2M in operating cash flow, capex of $486K consumed most of it, leaving -$53.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Talis Biomedical Corp passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Talis Biomedical Corp generates $0.86 in operating cash flow (-$53.2M OCF vs -$62.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Talis Biomedical Corp generated $2.1M in revenue in fiscal year 2023. This represents a decrease of 55.7% from the prior year.
Talis Biomedical Corp's EBITDA was -$66.0M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 37.9% from the prior year.
Talis Biomedical Corp generated -$53.7M in free cash flow in fiscal year 2023, representing cash available after capex. This represents an increase of 47.2% from the prior year.
Talis Biomedical Corp reported -$62.0M in net income in fiscal year 2023. This represents an increase of 45.1% from the prior year.
Talis Biomedical Corp earned $-34.12 per diluted share (EPS) in fiscal year 2023. This represents an increase of 45.6% from the prior year.
Talis Biomedical Corp held $76.7M in cash against $0 in long-term debt as of fiscal year 2023.
Talis Biomedical Corp had 2M shares outstanding in fiscal year 2023. This represents an increase of 0.6% from the prior year.
Talis Biomedical Corp's gross margin was 98.1% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is up 172.5 percentage points from the prior year.
Talis Biomedical Corp's operating margin was -3131.0% in fiscal year 2023, reflecting core business profitability. This is down 738.2 percentage points from the prior year.
Talis Biomedical Corp's net profit margin was -2905.7% in fiscal year 2023, showing the share of revenue converted to profit. This is down 557.1 percentage points from the prior year.
Talis Biomedical Corp invested $40.7M in research and development in fiscal year 2023. This represents a decrease of 42.5% from the prior year.
Talis Biomedical Corp invested $486K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 69.9% from the prior year.
TLIS Income Statement
| Metric | Q2'24 | Q1'24 | Q2'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $73K-62.6% | $195K+39.3% | $140K-88.5% | $1.2M+373.9% | $257K-67.7% | $796K+39.2% | $572K |
| Cost of Revenue | $0-100.0% | $6K-25.0% | $8K+33.3% | $6K-70.0% | $20K-99.1% | $2.3M+88.7% | $1.2M-5.1% | $1.3M |
| Gross Profit | $0-100.0% | $67K-64.2% | $187K+39.6% | $134K-88.8% | $1.2M+157.7% | -$2.1M-371.6% | -$440K+39.7% | -$730K |
| R&D Expenses | $1.6M-36.8% | $2.5M-68.5% | $8.0M-3.1% | $8.3M-39.8% | $13.8M-9.5% | $15.2M-13.0% | $17.5M+0.9% | $17.4M |
| SG&A Expenses | $8.0M-31.5% | $11.7M+76.5% | $6.6M-25.0% | $8.8M+37.6% | $6.4M-40.7% | $10.8M+22.3% | $8.8M-3.8% | $9.2M |
| Operating Income | -$9.6M+32.2% | -$14.1M+2.3% | -$14.5M+14.8% | -$17.0M+10.7% | -$19.0M+32.4% | -$28.1M-5.0% | -$26.8M+1.8% | -$27.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$8.8M+32.1% | -$13.0M+3.2% | -$13.5M+14.2% | -$15.7M+12.1% | -$17.8M+33.8% | -$26.9M-3.5% | -$26.0M+3.7% | -$27.0M |
| EPS (Diluted) | $-4.86+32.0% | $-7.15 | $-7.39+14.3% | $-8.62+12.4% | $-9.84+69.3% | $-32.07-122.1% | $-14.44+3.8% | $-15.01 |
TLIS Balance Sheet
| Metric | Q2'24 | Q1'24 | Q2'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $72.7M-11.9% | $82.5M-12.9% | $94.7M-11.7% | $107.2M-19.4% | $133.1M-21.4% | $169.3M-12.8% | $194.1M-12.4% | $221.7M |
| Current Assets | $63.6M-10.6% | $71.2M-8.4% | $77.7M-13.2% | $89.5M-22.5% | $115.6M-13.3% | $133.3M-11.4% | $150.4M-13.6% | $174.0M |
| Cash & Equivalents | $59.9M-14.9% | $70.3M-8.3% | $76.7M-12.8% | $88.0M-22.1% | $113.0M-13.2% | $130.2M-9.5% | $143.8M-13.1% | $165.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $2.0M-8.7% | $2.2M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $24.1M-6.7% | $25.8M+1.0% | $25.6M-0.4% | $25.7M+12.0% | $22.9M-46.1% | $42.6M+2.0% | $41.7M-6.6% | $44.7M |
| Current Liabilities | $8.2M-13.5% | $9.5M+8.0% | $8.8M+3.8% | $8.4M-24.4% | $11.2M-11.8% | $12.7M+11.4% | $11.4M-18.2% | $13.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $48.6M-14.2% | $56.7M-18.0% | $69.1M-15.3% | $81.6M-25.9% | $110.1M-13.1% | $126.7M-16.8% | $152.4M-13.9% | $177.0M |
| Retained Earnings | -$561.8M-1.6% | -$553.0M-2.4% | -$540.0M-2.6% | -$526.5M-6.2% | -$495.8M-3.7% | -$478.0M-6.0% | -$451.0M-6.1% | -$425.0M |
TLIS Cash Flow Statement
| Metric | Q2'24 | Q1'24 | Q2'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.3M-76.3% | -$6.4M+43.4% | -$11.4M-1.9% | -$11.1M+32.3% | -$16.5M-21.6% | -$13.5M+35.0% | -$20.8M+5.4% | -$22.0M |
| Capital Expenditures | $0 | $0+100.0% | -$93K-232.9% | $70K+191.7% | $24K-51.0% | $49K-94.3% | $860K+332.2% | $199K |
| Free Cash Flow | -$11.3M-76.3% | -$6.4M+43.9% | -$11.4M-2.1% | -$11.2M+32.0% | -$16.5M-21.3% | -$13.6M+37.3% | -$21.7M+2.4% | -$22.2M |
| Investing Cash Flow | $84K+180.0% | $30K-67.7% | $93K+232.9% | -$70K-191.7% | -$24K+51.0% | -$49K+94.3% | -$860K-332.2% | -$199K |
| Financing Cash Flow | $0-100.0% | $2K | $0 | $0-100.0% | $33K | $0-100.0% | $92K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TLIS Financial Ratios
| Metric | Q2'24 | Q1'24 | Q2'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 91.8%-4.1pp | 95.9%+0.2pp | 95.7%-2.7pp | 98.4%+905.8pp | -807.4%-752.1pp | -55.3%+72.3pp | -127.6% |
| Operating Margin | N/A | -19338.4%-11925.0pp | -7413.3%+4708.8pp | -12122.1%-10562.4pp | -1559.7%+9379.2pp | -10938.9%-7573.8pp | -3365.1%+1402.9pp | -4768.0% |
| Net Margin | N/A | -17856.2%-10953.6pp | -6902.6%+4298.9pp | -11201.4%-9737.5pp | -1464.0%+9014.3pp | -10478.2%-7209.2pp | -3269.0%+1453.2pp | -4722.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.2%+3.6pp | -15.8%-1.6pp | -14.2%+0.4pp | -14.6%-1.2pp | -13.4%+2.5pp | -15.9%-2.5pp | -13.4%-1.2pp | -12.2% |
| Current Ratio | 7.76+0.2 | 7.51-1.3 | 8.86-1.7 | 10.60+0.3 | 10.34-0.2 | 10.52-2.7 | 13.22+0.7 | 12.51 |
| Debt-to-Equity | 0.50+0.0 | 0.46+0.1 | 0.37+0.1 | 0.31+0.1 | 0.21-0.1 | 0.34+0.1 | 0.27+0.0 | 0.25 |
| FCF Margin | N/A | -8804.1%-2932.3pp | -5871.8%+2138.2pp | -8010.0%-6656.2pp | -1353.8%+3934.9pp | -5288.7%-2564.8pp | -2723.9%+1159.3pp | -3883.2% |
Similar Companies
Frequently Asked Questions
What is Talis Biomedical Corp's annual revenue?
Talis Biomedical Corp (TLIS) reported $2.1M in total revenue for fiscal year 2023. This represents a -55.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Talis Biomedical Corp's revenue growing?
Talis Biomedical Corp (TLIS) revenue declined by 55.7% year-over-year, from $4.8M to $2.1M in fiscal year 2023.
Is Talis Biomedical Corp profitable?
No, Talis Biomedical Corp (TLIS) reported a net income of -$62.0M in fiscal year 2023, with a net profit margin of -2905.7%.
What is Talis Biomedical Corp's earnings per share (EPS)?
Talis Biomedical Corp (TLIS) reported diluted earnings per share of $-34.12 for fiscal year 2023. This represents a 45.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Talis Biomedical Corp's EBITDA?
Talis Biomedical Corp (TLIS) had EBITDA of -$66.0M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is Talis Biomedical Corp's gross margin?
Talis Biomedical Corp (TLIS) had a gross margin of 98.1% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Talis Biomedical Corp's operating margin?
Talis Biomedical Corp (TLIS) had an operating margin of -3131.0% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Talis Biomedical Corp's net profit margin?
Talis Biomedical Corp (TLIS) had a net profit margin of -2905.7% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Talis Biomedical Corp's free cash flow?
Talis Biomedical Corp (TLIS) generated -$53.7M in free cash flow during fiscal year 2023. This represents a 47.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Talis Biomedical Corp's operating cash flow?
Talis Biomedical Corp (TLIS) generated -$53.2M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Talis Biomedical Corp's total assets?
Talis Biomedical Corp (TLIS) had $94.7M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Talis Biomedical Corp's capital expenditures?
Talis Biomedical Corp (TLIS) invested $486K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Talis Biomedical Corp spend on research and development?
Talis Biomedical Corp (TLIS) invested $40.7M in research and development during fiscal year 2023.
How many shares does Talis Biomedical Corp have outstanding?
Talis Biomedical Corp (TLIS) had 2M shares outstanding as of fiscal year 2023.
What is Talis Biomedical Corp's current ratio?
Talis Biomedical Corp (TLIS) had a current ratio of 8.86 as of fiscal year 2023, which is generally considered healthy.
What is Talis Biomedical Corp's debt-to-equity ratio?
Talis Biomedical Corp (TLIS) had a debt-to-equity ratio of 0.37 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Talis Biomedical Corp's return on assets (ROA)?
Talis Biomedical Corp (TLIS) had a return on assets of -65.5% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Talis Biomedical Corp's cash runway?
Based on fiscal year 2023 data, Talis Biomedical Corp (TLIS) had $76.7M in cash against an annual operating cash burn of $53.2M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Talis Biomedical Corp's Piotroski F-Score?
Talis Biomedical Corp (TLIS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Talis Biomedical Corp's earnings high quality?
Talis Biomedical Corp (TLIS) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Talis Biomedical Corp?
Talis Biomedical Corp (TLIS) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.